Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Surgical Case Reports|February 28, 2024
A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulationRie Shimizu, Kenichi Suda, Toshiki Takemoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2012
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutationYoshihiko Fujita, Kenichi Suda, Hideharu Kimura, et al.
Respiratory Investigation|December 3, 2014
Recent evidence, advances, and current practices in surgical treatment of lung cancerKenichi Suda, Katsuaki Sato, Hiroshi Mizuuchi, et al.
Clinical Lung Cancer|October 14, 2020
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five CasesKenichi Suda, Kazuko Sakai, Keiko Obata, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cellsYuichi Sesumi, Kenichi Suda, Hiroshi Mizuuchi, et al.
Plos One|April 16, 2015
Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinibHiroshi Mizuuchi, Kenichi Suda, Katsuaki Sato, et al.
Journal of Hematology & Oncology|June 11, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutationToshio Fujino, Kenichi Suda, Takamasa Koga, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2011
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancersKenji Tomizawa, Kenichi Suda, Ryoichi Onozato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR MutationKenichi Suda, Isao Murakami, Hui Yu, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Surgical Case Reports|February 28, 2024
A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulationRie Shimizu, Kenichi Suda, Toshiki Takemoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2012
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutationYoshihiko Fujita, Kenichi Suda, Hideharu Kimura, et al.
Respiratory Investigation|December 3, 2014
Recent evidence, advances, and current practices in surgical treatment of lung cancerKenichi Suda, Katsuaki Sato, Hiroshi Mizuuchi, et al.
Clinical Lung Cancer|October 14, 2020
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five CasesKenichi Suda, Kazuko Sakai, Keiko Obata, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cellsYuichi Sesumi, Kenichi Suda, Hiroshi Mizuuchi, et al.
Plos One|April 16, 2015
Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinibHiroshi Mizuuchi, Kenichi Suda, Katsuaki Sato, et al.
Journal of Hematology & Oncology|June 11, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutationToshio Fujino, Kenichi Suda, Takamasa Koga, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2011
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancersKenji Tomizawa, Kenichi Suda, Ryoichi Onozato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR MutationKenichi Suda, Isao Murakami, Hui Yu, et al.
Pageof 13